CTMX vs TROW · rev $138.1M vs P/E 12, rev $7.09B
CytomX Therapeutics Inc (CTMX) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported CTMX revenue for 2024-12-31 was $138.1M. Net income was $31.9M. Revenue was up 36.4% from 2023-12-31 to 2024-12-31. CTMX currently screens at market cap $653.1M.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
CTMX currently screens at market cap $653.1M. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the CTMX and TROW stock pages for the full models.
Not investment advice.